Drug Profile
Olea pollen allergy immunotherapy - Laboratorios LETI
Latest Information Update: 04 May 2015
Price :
$50
*
At a glance
- Originator Laboratorios LETI
- Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Seasonal allergic rhinitis
Most Recent Events
- 31 Jan 2013 Laboratorios Leti completes the phase III OLEA trial in Seasonal allergic rhinitis in Spain (NCT00831025)
- 16 Oct 2012 Phase-III development is ongoing in Spain
- 10 Aug 2011 Laboratorios Leti completes enrolment in its phase III trial for Seasonal allergic rhinitis in Spain (NCT00831025)